Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Transducer Mechanism: Nuclear Receptors

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

Menopause

Menopause

Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...

Tissues

Tissues

Cells with similar structure and function are grouped into tissues. A group of tissues with a specialized function is called an organ. There are four main types of tissue in vertebrates: epithelial, connective, muscle, and nervous.

Menses Phase

Menses Phase

The uterine cycle begins with the menstrual phase, which is considered day one of the cycle and typically lasts about five days. This phase is characterized by the degeneration and shedding of the stratum functionalis, the functional layer of the endometrium.
When fertilization does not occur, the corpus luteum deteriorates, causing a significant drop in the levels of estrogen and progesterone in the body. This hormonal decrease triggers the release of prostaglandins, which cause the uterine...

Tissue-Drug Binding: Localization of Drugs and its Significance

Tissue-Drug Binding: Localization of Drugs and its Significance

Body tissues, comprising approximately 40% of the body weight, are crucial in drug distribution and localization. These tissues can serve as drug storage sites, competing with plasma binding sites for drug molecules.
Drugs can bind to different tissue components, enhancing their distribution and localization. The factors influencing drug localization in tissues include the drug's lipophilicity, structural characteristics, tissue perfusion rate, and pH differences. These factors determine the...

EDTA: Auxiliary Complexing Reagents

EDTA: Auxiliary Complexing Reagents

EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Metabolic and transcriptional effects of bazedoxifene/conjugated estrogens in a model of obesity-associated breast cancer risk.

JCI insight·2025

Same author

Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.

Clinical breast cancer·2025

Same author

Overcoming challenges in conducting early phase breast cancer prevention trials: Bazedoxifene and conjugated estrogens vs waitlist control.

Contemporary clinical trials·2024

Same author

Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer.

Breast cancer research : BCR·2024

Same author

Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.

Menopause (New York, N.Y.)·2024

Same author

Epigenetic and transcriptome responsiveness to ER modulation by tissue selective estrogen complexes in breast epithelial and breast cancer cells.

PloS one·2022

Search research articles

Related Experiment Video

Updated: May 9, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Tissue-selective estrogen complexes for postmenopausal women.

Sebastian Mirkin¹, Barry S Komm

¹Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA.

|July 16, 2013

Summary

This summary is machine-generated.

Tissue selective estrogen complex (TSEC) offers an alternative to hormone therapy for menopausal symptom relief and osteoporosis prevention. This new treatment effectively manages symptoms without concerning side effects on uterine and breast tissues.

Keywords:

BMD BZA Bazedoxifene CE EPT ER LAS LDL-C MCF-7 MENQOL MS-TSQ Menopause Symptoms Treatment Satisfaction Questionnaire Menopause-Specific Quality of Life Michigan Cancer Foundation-7 Osteoporosis RLX SERM SERMs SMART Selective estrogens, Menopause, And Response to Therapy TSEC TSECs VMS VTE VVA Vasomotor symptoms Vulvar/vaginal atrophy bazedoxifene bone mineral density conjugated estrogens estrogen receptor estrogen-progestin therapy lasofoxifene low-density lipoprotein cholesterol raloxifene selective estrogen receptor modulator tissue selective estrogen complex vasomotor symptoms venous thromboembolic event vulvar/vaginal atrophy

More Related Videos

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Related Experiment Videos

Last Updated: May 9, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

Published on: March 17, 2016

Area of Science:

Reproductive endocrinology and women's health.

Background:

Estrogen plus progestogen therapy (EPT) manages menopausal symptoms and osteoporosis but has safety concerns.
Tissue selective estrogen complex (TSEC) offers an alternative, combining selective estrogen receptor modulators (SERMs) with estrogens.
Bazedoxifene (BZA) with conjugated estrogens (CE) is the first TSEC in advanced clinical development.

Purpose of the Study:

To evaluate the efficacy and safety of bazedoxifene/conjugated estrogens (BZA/CE) as a TSEC for postmenopausal women.
To assess BZA/CE's impact on menopausal symptoms, bone health, and endometrial/breast tissue.
To compare BZA/CE with traditional hormone therapies.

Main Methods:

Preclinical in vitro and in vivo studies to assess BZA's tissue-selective effects.
Clinical trials evaluating BZA/CE for menopausal symptom management and bone mineral density.
Monitoring of endometrial and breast tissue response, bone turnover markers, sleep, and quality of life.

Main Results:

BZA/CE significantly improved menopausal symptoms like hot flushes and vulvar/vaginal atrophy.
Significant increases in bone mineral density and reductions in bone turnover markers were observed.
BZA/CE demonstrated a neutral effect on endometrial and breast tissue, inhibiting estrogenic stimulation.

Conclusions:

BZA/CE effectively treats menopausal symptoms and prevents osteoporosis without endometrial or breast stimulation.
This TSEC provides the benefits of estrogen therapy while mitigating safety concerns associated with EPT.
BZA/CE represents a safe and effective treatment option for symptomatic postmenopausal women.